Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(2.22)
# 2,843
Out of 5,042 analysts
34
Total ratings
50%
Success rate
-3.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JSPR Jasper Therapeutics | Maintains: Outperform | $20 → $14 | $2.37 | +490.72% | 4 | Sep 22, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $207 → $222 | $227.99 | -2.63% | 5 | Sep 22, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $77 → $89 | $70.02 | +27.11% | 3 | Aug 8, 2025 | |
| PRQR ProQR Therapeutics | Initiates: Outperform | $5 | $2.94 | +70.07% | 1 | Apr 29, 2025 | |
| MNMD Mind Medicine (MindMed) | Initiates: Outperform | $23 | $12.38 | +85.78% | 1 | Jan 28, 2025 | |
| CABA Cabaletta Bio | Downgrades: In-Line | $15 → $6 | $2.47 | +142.91% | 2 | Dec 20, 2024 | |
| ARGX argenx SE | Maintains: Outperform | $675 → $706 | $817.32 | -13.62% | 4 | Nov 21, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $179 → $170 | $22.81 | +645.29% | 9 | Nov 7, 2024 | |
| FHTX Foghorn Therapeutics | Initiates: Outperform | $20 | $4.07 | +391.40% | 1 | Aug 19, 2024 | |
| KRYS Krystal Biotech | Maintains: Outperform | $201 → $206 | $186.13 | +10.68% | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $2.15 | +923.26% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $10 | $2.45 | +308.16% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $57.29 | +4.73% | 1 | Oct 5, 2022 |
Jasper Therapeutics
Sep 22, 2025
Maintains: Outperform
Price Target: $20 → $14
Current: $2.37
Upside: +490.72%
AbbVie
Sep 22, 2025
Maintains: Outperform
Price Target: $207 → $222
Current: $227.99
Upside: -2.63%
Mirum Pharmaceuticals
Aug 8, 2025
Maintains: Outperform
Price Target: $77 → $89
Current: $70.02
Upside: +27.11%
ProQR Therapeutics
Apr 29, 2025
Initiates: Outperform
Price Target: $5
Current: $2.94
Upside: +70.07%
Mind Medicine (MindMed)
Jan 28, 2025
Initiates: Outperform
Price Target: $23
Current: $12.38
Upside: +85.78%
Cabaletta Bio
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $2.47
Upside: +142.91%
argenx SE
Nov 21, 2024
Maintains: Outperform
Price Target: $675 → $706
Current: $817.32
Upside: -13.62%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $22.81
Upside: +645.29%
Foghorn Therapeutics
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $4.07
Upside: +391.40%
Krystal Biotech
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $186.13
Upside: +10.68%
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $2.15
Upside: +923.26%
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $2.45
Upside: +308.16%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $57.29
Upside: +4.73%